Salute e Benessere
Newronika Closes €13.6 Million Series B Financing to Accelerate Development of Adaptive DBS Platform
Newronika's continued momentum – evidenced by recent The Michael J. Fox Foundation grant and IDE approval, and now a substantial funding round – underscores the company's central mission: to champion a paradigm shift in neuromodulation. Adaptive DBS represents the future of personalized brain stimulation, and Newronika remains dedicated to leading that evolution.
said Dr. Lorenzo Rossi , Co-Founder and CEO of Newronika.
said Maria Cristina Porta , ENEA Tech e Biomedical General Manager
Davide Turco , CEO of Indaco said:
said Claudio Giuliano , Chairman of Newronika
ENEA Tech e Biomedical is an Italian foundation supporting high-impact projects in biotechnology, medical devices, and life sciences, focusing on transformative solutions for global healthcare challenges. (https://www.fondazioneneatechbiomedical.it)
Indaco Venture Partners SGR is one of Italy's largest venture capital firms, investing equally through its Indaco Ventures I fund and Indaco Venture I - Lombardia Parallel Fund to support cutting-edge innovations in healthcare and technology. Indaco Venture I - Lombardia Parallel Fund is an investment fund managed by Indaco Venture SGR S.p.A., selected through a public procedure by Regione Lombardia as part of the regional initiative Lombardia Venture, a fund of funds financed by ERDF PR 21-27 (Action 1.3.2) and managed by Finlombarda, which aims to support access to risk capital by
Lombardy companies and to attract risk capital investment in companies through a partnership approach with private investors. Indaco Venture I - Lombardia Parallel Fund systematically co-invests with the Indaco Venture I Fund in companies operating in the region with high potential for technological innovation. (www.indacosgr.com)
Innogest SGR is a venture capital firm specializing in med-tech and digital health, leveraging its extensive experience to foster innovative healthcare startups. (https://www.innogestcapital.com)
Wille Finance is a Swiss-based multi-family office committed to impactful investments in healthcare, technology, and other transformative sectors. (https://www.willefinance.com)
TNBT Capital is a Paris -based investor focused on pioneering technologies in neuromodulation and neurotechnology. (https://www.tnbtcapital.com)
F3F is an Italian venture capital firm investing in innovative med-tech companies that are redefining patient care.
Newronika is transforming deep brain stimulation (DBS) through its adaptive platform that uses real-time patient data to optimize therapy. Headquartered in Milan, Italy , the company is committed to advancing neuromodulation beyond conventional limitations. With ongoing research collaborations, a CE Mark for its technology, and now an Investigational Device Exemption from the FDA, Newronika stands at the forefront of next-generation therapeutic innovation for neurological disorders.
For more information, visit www.newronika.com or follow us on LinkedIn.
Logo - https://mma.prnewswire.com/media/2612569/5150136/Newronika_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/newronika-closes-13-6-million-series-b-financing-to-accelerate-development-of-adaptive-dbs-platform-302374929.html